Spry Malinda, Scott Tim, Pierce Heather, D'Orazio John A
The Graduate Center for Toxicology, University of Kentucky College of Medicine, Lexington, KY 40536-0096, USA.
Front Biosci. 2007 May 1;12:4191-207. doi: 10.2741/2380.
Every living organism is exposed to numerous genomic insults on a daily basis as a consequence of cellular metabolism and exposure to environmental agents capable of interacting with the genome (e.g. chemicals, toxins, pollutants, UV and ionizing radiation) (1). Maintenance of the integrity of the genome is paramount to the survival and propagation of a species and involves the continuous activity of a variety of DNA repair pathways. Inherited mutations in genes involved in DNA damage recognition and repair lead to disease by destabilization of the genome and increased mutagenesis. In fact, it is common for cancer cells to exhibit loss of genomic stability presumably as a result of clonally acquired mutations in DNA repair genes (2). Currently, roughly 150 DNA repair genes have been identified in humans (3) and a variety of familial cancer predisposition and/or premature aging syndromes are now linked to various loss-of-function mutations in these genes (4). Genetic interaction between DNA repair pathways and global cell differentiation pathways is supported by phenotypic similarities between inactivating mutations in a DNA repair, cell cycle arrest and apoptosis proteins. Though there is clearly some degree of functional redundancy between DNA repair pathways for correction of specific DNA lesions, the particular clinical characteristics of a repair defect can be predicted by the specific repair pathway affected (5). Patients with cancer predisposition syndromes often have multiple family members affected by cancer, develop cancer at an early age, and are at risk for developing multiple primary tumors over time (6, 7). Though patients with identifiable cancer predisposition syndromes are rare, defining their molecular defects has led to widespread applicability by uncovering relevant molecular pathways that are perturbed via somatic (non-inherited) mutations in the majority of sporadic cancers. In this review, we describe general molecular mechanisms of major forms of DNA repair and illustrate clinical consequences of deficiencies in these pathways. For more in depth detail, the reader is referred to several recent reviews and texts (2, 8-13).
由于细胞代谢以及接触能够与基因组相互作用的环境因素(如化学物质、毒素、污染物、紫外线和电离辐射),每种生物每天都会受到无数次基因组损伤(1)。基因组完整性的维持对于物种的生存和繁衍至关重要,这涉及多种DNA修复途径的持续作用。参与DNA损伤识别和修复的基因发生遗传突变会导致基因组不稳定和诱变增加,从而引发疾病。事实上,癌细胞通常表现出基因组稳定性丧失,这可能是由于DNA修复基因中克隆性获得的突变所致(2)。目前,人类已鉴定出约150个DNA修复基因(3),多种家族性癌症易感性和/或早衰综合征现在与这些基因中的各种功能丧失突变相关联(4)。DNA修复途径与整体细胞分化途径之间的遗传相互作用得到了DNA修复、细胞周期停滞和凋亡蛋白失活突变之间表型相似性的支持。尽管在纠正特定DNA损伤的DNA修复途径之间显然存在一定程度的功能冗余,但可以通过受影响的特定修复途径预测修复缺陷的特定临床特征(5)。患有癌症易感性综合征的患者通常有多个家庭成员患癌,发病年龄较早,并且随着时间的推移有发生多种原发性肿瘤的风险(6,7)。尽管患有可识别的癌症易感性综合征的患者很少见,但确定其分子缺陷通过揭示在大多数散发性癌症中因体细胞(非遗传性)突变而受到干扰的相关分子途径,已导致广泛的应用。在本综述中,我们描述了主要DNA修复形式的一般分子机制,并阐述了这些途径缺陷的临床后果。如需更深入的详细信息,请读者参考最近的几篇综述和文献(2,8 - 13)。